Edition:
United States

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

7.20USD
4:00pm EDT
Change (% chg)

$0.27 (+3.90%)
Prev Close
$6.93
Open
$6.77
Day's High
$7.20
Day's Low
$6.77
Volume
725
Avg. Vol
3,208
52-wk High
$25.11
52-wk Low
$4.94

Latest Key Developments (Source: Significant Developments)

Sonoma Pharmaceuticals Reports Qtrly Loss Per Share $2.45
Monday, 8 Jul 2019 04:03pm EDT 

July 8 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS REPORTS FISCAL YEAR AND FOURTH QUARTER 2019 FINANCIAL RESULTS.Q4 REVENUE ROSE 20 PERCENT TO $4.4 MILLION.QTRLY LOSS PER SHARE $2.45.AS OF MARCH 31, 2019, SONOMA HAD CASH AND CASH EQUIVALENTS OF $3.7 MILLION.  Full Article

Sonoma Pharmaceuticals Announces Substantial Cost-Cutting Measures
Tuesday, 12 Mar 2019 06:30pm EDT 

Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES SUBSTANTIAL COST-CUTTING MEASURES.SONOMA PHARMACEUTICALS INC - ANNOUNCED SUBSTANTIAL COST-CUTTING MEASURES, INCLUDING REDUCTIONS TO COMPANY'S WORKFORCE AND MANAGEMENT.SONOMA PHARMACEUTICALS INC - EXPECTS THAT COST ELIMINATIONS WILL DIRECTLY IMPACT BOTTOM LINE BY REDUCING COMPANY'S OPERATING LOSS.SONOMA PHARMACEUTICALS INC - CONTINUALLY EVALUATES AND REDUCES EXPENSES INCLUDING CURRENT REDUCTIONS IN ITS WORKFORCE.SONOMA PHARMACEUTICALS INC - PRIMARY REDUCTIONS WERE IN COMPANY'S CONSULTING EXPENSES, MANUFACTURING FORCE AND MANUFACTURING EXPENSES.SONOMA PHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS WERE $6.5 MILLION AT DECEMBER 31, 2018.SONOMA PHARMACEUTICALS INC - CUTS WILL INCLUDE CERTAIN ONE-TIME RESTRUCTURING COSTS.SONOMA PHARMACEUTICALS INC - EXPECTS TO LOWER COSTS IN FOURTH QUARTER OF FY 2019 AND GOING FORWARD.  Full Article

Sonoma Pharmaceuticals Says Appointed Frederick Sandford As CEO
Friday, 14 Dec 2018 05:13pm EST 

Dec 14 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS - EFFECTIVE DEC 11, 2018, BOARD APPOINTED FREDERICK (BUBBA) SANDFORD AS CEO AND INTERIM CFO FOR AN INITIAL TERM OF NINE MONTHS.SONOMA PHARMACEUTICALS- EFFECTIVE DEC 12, JIM SCHUTZ & ROBERT MILLER RESIGNED FROM THEIR POSITIONS AS CEO & PRESIDENT & CFO & SECRETARY, RESPECTIVELY.  Full Article

Montreux Equity Partners-Daniel Turner, On Behalf Of Montreux, Delivered Second Letter To Board Of Sonoma Pharmaceuticals
Tuesday, 20 Nov 2018 04:30pm EST 

Nov 20 (Reuters) - Sonoma Pharmaceuticals Inc ::MONTREUX EQUITY PARTNERS V - ON NOV 19, DANIEL TURNER, ON BEHALF OF MONTREUX EQUITY PARTNERS, DELIVERED SECOND LETTER TO BOARD OF SONOMA PHARMACEUTICALS.MONTREUX EQUITY PARTNERS V - IN LETTER, TURNER NOTED THAT SONOMA PHARMACEUTICALS BOARD HAD FAILED TO RESPOND TO PREVIOUS LETTER DATED NOVEMBER 2.MONTREUX EQUITY PARTNERS V - LETTER ALSO NOTED THAT SONOMA PHARMACEUTICALS BOARD FAILED TO TAKE ADVICE OUTLINED IN ORIGINAL LETTER CO ABANDON EQUITY FINANCING.  Full Article

Collidion Announces Settlement Of Sonoma Litigation
Monday, 12 Nov 2018 07:00am EST 

Nov 12 (Reuters) - Sonoma Pharmaceuticals Inc ::COLLIDION ANNOUNCES SETTLEMENT OF SONOMA LITIGATION.SONOMA PHARMACEUTICALS INC - TERMS OF SETTLEMENT ARE OTHERWISE BEING KEPT CONFIDENTIAL.  Full Article

Montreux Equity Partners V Reports 8.8 Pct Stake In Sonoma Pharmaceuticals As Of Nov 2, 2018
Monday, 5 Nov 2018 05:58pm EST 

Nov 5 (Reuters) - Montreux Equity Partners V::MONTREUX EQUITY PARTNERS V, L.P. REPORTS 8.8% STAKE IN SONOMA PHARMACEUTICALS INC AS OF NOVEMBER 2, 2018 - SEC FILING.MONTREUX EQUITY PARTNERS V - NOW HAVE INTENT TO INFLUENCE POLICIES OF SONOMA PHARMACEUTICALS INC.MONTREUX EQUITY PARTNERS V - PROPOSE SHARON BARBARI, JAY BIRNBAUM, JERRY MCLAUGHLIN RESIGN FROM SONOMA BOARD .MONTREUX EQUITY PARTNERS V - ON NOVEMBER 2, 2018, DANIEL TURNER ON BEHALF OF MEP V, SENT LETTER TO BOARD OF SONOMA PHARMACEUTICALS.MONTREUX EQUITY PARTNERS V - PROPOSED THAT SONOMA PHARMACEUTICALS SHOULD IMMEDIATELY REDUCE BOARD COMPENSATION.MONTREUX EQUITY PARTNERS V - PROPOSED THAT SONOMA PHARMACEUTICALS SHOULD PURSUE APPROPRIATE STRATEGIC ALTERNATIVES, INCLUDING SALE.MONTREUX EQUITY PARTNERS V - PROPOSED SONOMA PHARMACEUTICALS SHOULD IMMEDIATELY ELIMINATE TAKEOVER DEFENSES, INCLUDING POISON PILL RIGHTS PLAN.  Full Article

Sonoma Pharma Announces Licensing Of Antimicrobial Hypochlorous Acid Solution For Management Of Blepharitis In The Spanish/Portuguese Markets
Wednesday, 26 Sep 2018 07:05am EDT 

Sept 26 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES LICENSING OF ANTIMICROBIAL HYPOCHLOROUS ACID SOLUTION FOR MANAGEMENT OF BLEPHARITIS IN THE SPANISH/PORTUGUESE MARKETS TO BRILL PHARMA, S.L..SONOMA PHARMACEUTICALS - OCUDOX IS EXPECTED TO BECOME AVAILABLE IN SPAIN AND PORTUGAL BEGINNING EARLY 2019.  Full Article

Sonoma Pharmaceuticals Inc - QTRLY Loss Per Share $0.55
Wednesday, 8 Aug 2018 04:05pm EDT 

Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS REPORTS FIRST QUARTER FY 2019 FINANCIAL RESULTS.Q1 REVENUE ROSE 14 PERCENT TO $4.4 MILLION.QTRLY LOSS PER SHARE $0.55.  Full Article

Sonoma Pharma Enters Into Deal For Distribution Of Dermatology Products Into Brazil
Tuesday, 5 Jun 2018 07:05am EDT 

June 5 (Reuters) - Sonoma Pharmaceuticals Inc ::U.SK, DERMATOLOGY ARM OF BRAZILIAN NC GROUP, AND SONOMA PHARMACEUTICALS ENTER INTO LICENSE AGREEMENT FOR EXCLUSIVE RIGHTS TO SONOMA’S DERMATOLOGY PRODUCTS IN BRAZIL.SONOMA PHARMACEUTICALS - ENTERED INTO DEAL FOR EXCLUSIVE DISTRIBUTION OF MULTIPLE SONOMA DERMATOLOGY PRODUCTS INTO BRAZIL.SONOMA PHARMACEUTICALS INC - FIRST PRODUCTS ARE EXPECTED TO HIT MARKET IN AUGUST 2018.  Full Article

Sonoma Pharma Gets Three New UAE Regulatory Approvals
Tuesday, 9 Jan 2018 07:05am EST 

Jan 9 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS.SONOMA PHARMACEUTICALS INC - ANTICIPATE LAUNCHING ALL THREE PRODUCTS ACROSS UNITED ARAB EMIRATES IN FEBRUARY 2018.  Full Article